Product Details:
| Strength | 100 IU/ml |
| Packaging Size | 3 ml |
| Composition | 100U/ml |
| Packaging Type | Pack |
| Brand | Basaglar Insulin |
| Manufacturer | Lilly |
| Prescription/Non-Prescription | Prescription |
| Country of Origin | Made in India |
Basaglar – Insulin Glargine Injection
Basaglar is a brand of Insulin Glargine, which is a long-acting (basal) insulin analog used to control blood sugar in diabetes mellitus.
🔹 CompositionActive ingredient: Insulin Glargine (rDNA origin).
Form: Prefilled injection pen (KwikPen) or cartridge, usually 100 units/mL solution for subcutaneous injection.
Insulin Glargine is a modified human insulin analog.
After subcutaneous injection, it forms microprecipitates in the tissue.
These slowly release insulin into the bloodstream over 24 hours.
Provides a steady, peakless, basal insulin level, mimicking the body’s natural background insulin.
It lowers blood glucose by:
Enhancing glucose uptake in muscle and fat.
Suppressing glucose production in the liver.
Type 1 Diabetes Mellitus – for basal insulin replacement, used along with mealtime (bolus) insulin.
Type 2 Diabetes Mellitus – when oral antidiabetic drugs are insufficient.
Can be used in adults and children (≥6 years old).
Individualized based on blood glucose monitoring.
Typically injected once daily, at the same time each day (morning or evening).
Starting dose in Type 2 diabetes: often 10 units once daily or 0.2 units/kg.
In Type 1 diabetes: given as part of a basal–bolus regimen (long-acting insulin + mealtime insulin).
(Exact dosing is always adjusted by physician based on blood sugar levels.)
🔹 Onset, Peak, DurationOnset: ~1–2 hours.
Peak: Minimal or no peak (provides steady effect).
Duration: Up to 24 hours (sometimes longer).
Common:
Hypoglycemia (low blood sugar – most important risk).
Injection site reactions (redness, swelling, itching).
Weight gain.
Swelling of hands/feet.
Serious (rare):
Severe hypoglycemia → seizures, unconsciousness.
Allergic reactions (rash, difficulty breathing).
Lipodystrophy (fat changes at injection sites).
Edema (fluid retention).
Rotate injection sites (to avoid lipodystrophy).
Do not mix with other insulins in the same syringe/pen.
Store unopened pens in the refrigerator (not freezer); once opened, can be kept at room temperature (below 30°C) for up to 28 days.
Monitor blood glucose regularly.
Dose adjustments required in: kidney/liver disease, illness, or major lifestyle changes (diet, exercise).
Hypoglycemia (must not inject when blood sugar is already low).
Hypersensitivity to insulin glargine or formulation components.
Product Details:
| Minimum Order Quantity | 1 Vial |
| Strength | 5 mg |
| Brand | Mounjaro 5 mg |
| Packaging Size | 0.5 ml |
| Packaging Type | Injection |
| Manufacturer | Lilly |
| Prescription | Yes |
| Usage / Application | weight loss |
| Storage Conditions | Cold Storage |
Tirzepatide 5 mg is a once-weekly injectable medication used to treat type 2 diabetes mellitus and for weight loss in adults with obesity or overweight with related health conditions. It’s marketed under the brand name Mounjaro (and Zepbound for weight loss in the U.S.).
It’s a dual incretin receptor agonist, meaning it mimics the action of two gut hormones:
GLP-1 (Glucagon-Like Peptide-1)
GIP (Glucose-Dependent Insulinotropic Polypeptide)
Synthetic dual GIP/GLP-1 receptor agonist.
Approved by the US FDA for:
Type 2 diabetes (as Mounjaro)
Chronic weight management in adults with obesity (as Zepbound)
Administered via subcutaneous injection once weekly.
| Hormone | Effect |
|---|---|
| GLP-1 | Increases insulin secretion, slows gastric emptying, reduces appetite |
| GIP | Enhances insulin release and promotes fat metabolism |
Tirzepatide activates both, resulting in:
Lower blood glucose
Improved insulin sensitivity
Reduced hunger
Significant fat loss
Comes in pre-filled injection pens or vials.
5 mg is usually a maintenance dose.
Typical titration schedule:
| Week | Dose |
|---|---|
| 1–4 | 2.5 mg (starting) |
| 5–8 | 5 mg |
| 9+ | 7.5 mg, 10 mg, 12.5 mg, or 15 mg as needed |
Dose is increased gradually to reduce gastrointestinal side effects.
| Condition | Effect |
|---|---|
| Type 2 Diabetes | Improves blood glucose control |
| Obesity / Overweight | Promotes fat loss and appetite suppression |
| Insulin Resistance / PCOS | (Off-label) may improve metabolic profile |
| Cardiovascular Risk | Potential benefit (being studied) |
Reduces HbA1c by up to 2.3%
Helps many patients reach HbA1c <7%
Average 12% to 22% body weight loss seen in trials
Higher than GLP-1 agonists like semaglutide (Ozempic, Wegovy)
Improved cholesterol and triglycerides
Reduced liver fat
Appetite suppression
Long-lasting effect (weekly dosing)
| Common | Occasional | Rare / Serious |
|---|---|---|
| Nausea | Vomiting | Pancreatitis |
| Diarrhea / Constipation | Dizziness | Gallstones |
| Loss of appetite | Fatigue | Kidney issues (from dehydration) |
| Injection site reactions | Burping | Severe hypoglycemia (with insulin or sulfonylureas) |
🟡 GI symptoms are most common, especially during dose escalation. Usually improve over time.
Additional Information:
Product Details:
| Minimum Order Quantity | 10 Strip |
| Strength | 500 mg |
| Pack Size | 20*10 Tablets |
| Pack Type | Box |
| Brand | GLYCOMET-500 SR Tablet |
| Shelf Life | 36 months |
| Usage | To Treat Gestational Diabetes |
| Country of Origin | Made in India |
Additional Information:
Product Details:
| Minimum Order Quantity | 10 Strip |
| Strength | 10 mg / 500 mg |
| Packaging Size | 4*7 Tablets |
| Packaging Type | Box |
| Brand | OXRAMET XR 10/500 TAB |
| Manufacturer | SUN |
| Shelf Life | 2 years |
Dapagliflozin (10 mg) + Metformin (500 mg) Tablet
Category: Oral anti-diabetic fixed-dose combination
Dapagliflozin → SGLT2 inhibitor
Metformin → Biguanide
Type 2 Diabetes Mellitus (T2DM)
Improves blood sugar control in adults when diet and exercise alone are not enough.
Combination works better than either drug alone.
Prevention of Diabetes Complications
Reduces risk of:
Heart disease (cardiovascular events)
Kidney disease progression (diabetic nephropathy)
Hospitalization for heart failure (dapagliflozin benefit)
Weight & Blood Pressure Benefits
Dapagliflozin promotes glucose loss via urine → mild weight loss & lower blood pressure.
Useful in overweight/obese diabetics.
Dapagliflozin (SGLT2 inhibitor): Blocks glucose reabsorption in kidneys → excess sugar excreted in urine → lowers blood glucose.
Metformin (Biguanide): Decreases liver glucose production + improves insulin sensitivity → better sugar uptake in muscles and fat.
👉 Together: Dual action → better blood sugar control + organ protection.
DosageUsually taken once or twice daily with meals (to reduce stomach upset from metformin).
Dose may be adjusted depending on blood sugar and kidney function.
Common:
Metformin: Nausea, diarrhea, stomach upset
Dapagliflozin: Increased urination, urinary tract infections, genital fungal infections
Serious but rare:
Lactic acidosis (from metformin, in kidney/liver failure)
Dehydration, low blood pressure (from dapagliflozin)
Diabetic ketoacidosis (rare, even if sugars are not very high)
Monitor kidney function (eGFR) regularly
Avoid in severe kidney/liver disease
Maintain good hydration to avoid dehydration & infections
Not usually recommended in Type 1 diabetes or during pregnancy/breastfeeding
Additional Information: